AI & Machine Learning
Bioinformatics
Sinopia Biosciences publishes PKA-II modulator data in Science TM
Sinopia's SB-0110 reduced levodopa-induced dyskinesia while boosting motor benefit in primate models, with first-in-human studies targeted for 2027.
Sinopia's SB-0110 reduced levodopa-induced dyskinesia while boosting motor benefit in primate models, with first-in-human studies targeted for 2027.
Bioinformatics
NorthStrive and Yuva Biosciences validate four ANT1-inducing compounds
Four AI-selected small molecules increased ANT1 expression in human skeletal muscle cells, advancing NorthStrive's muscle-preservation programme toward confirmatory
Four AI-selected small molecules increased ANT1 expression in human skeletal muscle cells, advancing NorthStrive's muscle-preservation programme toward confirmatory
Digital Health
Diagnostics
Firstsource and AppliedAI report 95% cuts in live AI deployments
Six months after a strategic equity deal, the partners say live deployments cut healthcare processing times by 93% and lifted admissions throughput up to tenfold.
Six months after a strategic equity deal, the partners say live deployments cut healthcare processing times by 93% and lifted admissions throughput up to tenfold.
Digital Health
Isle of Man names four winners of 2026 health innovation challenge
Four digital health companies were selected from 125 global entries to win the Isle of Man's annual Innovation Challenge on Health and Social Care.
Four digital health companies were selected from 125 global entries to win the Isle of Man's annual Innovation Challenge on Health and Social Care.
Biotech
HCLTech selected as IT transformation partner by Neste
HCLTech will lead IT service consolidation and AI-driven efficiency improvements for Neste as part of the Finnish renewables firm's performance programme.
HCLTech will lead IT service consolidation and AI-driven efficiency improvements for Neste as part of the Finnish renewables firm's performance programme.
Biologics
Absci reports clean Phase 1 safety data for anti-PRLR antibody ABS-201
Absci's AI-designed hair-loss antibody showed no serious adverse events across four SAD cohorts and a half-life of at least 65 days.
Absci's AI-designed hair-loss antibody showed no serious adverse events across four SAD cohorts and a half-life of at least 65 days.
Digital Health
CosmoFarm posts record $15m Q2 revenue on pharmacy network growth
The Athens-based pharmaceutical wholesaler added over 80 pharmacies in Q2 2026, lifting Cosmos Health's annualised revenue run-rate beyond $60 million.
The Athens-based pharmaceutical wholesaler added over 80 pharmacies in Q2 2026, lifting Cosmos Health's annualised revenue run-rate beyond $60 million.
Diagnostics
Bioinformatics
Adaptive Biotechnologies plans to spin out Immune Medicine unit
The Seattle biotech will separate its profitable clonoSEQ MRD diagnostics arm from its AI-driven immune medicine discovery platform by end of 2026.
The Seattle biotech will separate its profitable clonoSEQ MRD diagnostics arm from its AI-driven immune medicine discovery platform by end of 2026.
Diagnostics
Digital Health
Genomics
Nano Dimension signs term sheet to merge with Infinite Epigenetics
Nano Dimension is pivoting from digital manufacturing into epigenetic diagnostics via a proposed $890m combination with AI-powered Infinite Epigenetics.
Nano Dimension is pivoting from digital manufacturing into epigenetic diagnostics via a proposed $890m combination with AI-powered Infinite Epigenetics.
Diagnostics
Digital Health
Ceribell Clarity AI links seizure burden to neurological outcomes
A peer-reviewed study in Critical Care Medicine found Ceribell's AI algorithm associates high seizure burden with a 3.4-fold rise in death
A peer-reviewed study in Critical Care Medicine found Ceribell's AI algorithm associates high seizure burden with a 3.4-fold rise in death
Digital Health
Health Catalyst divests Vitalware to Med-Metrix for $147m
Health Catalyst will sell its mid-revenue cycle unit to fund AI investment and fully repay a $160m term loan.
Health Catalyst will sell its mid-revenue cycle unit to fund AI investment and fully repay a $160m term loan.
Diagnostics
Regulatory Science
Cellectar's iopofosine I 131 shows durable WM responses at 12 months
Phase 2b CLOVER WaM data show 83.6% ORR and 17.8-month median response duration, strengthening the case for accelerated FDA approval.
Phase 2b CLOVER WaM data show 83.6% ORR and 17.8-month median response duration, strengthening the case for accelerated FDA approval.